moxifloxacin + isoniazid + rifampin + pyrazinamide

This drug is a fixed-dose combination of four antibiotics—moxifloxacin, isoniazid, rifampin, and pyrazinamide—used in the treatment of active tuberculosis (TB). Each component has a distinct mechanism of action targeting *Mycobacterium tuberculosis*: - **Moxifloxacin** is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. - **Isoniazid** inhibits mycolic acid synthesis in the mycobacterial cell wall. - **Rifampin** inhibits DNA-dependent RNA polymerase in susceptible bacteria. - **Pyrazinamide** disrupts membrane transport and energy production in *M. tuberculosis*. This combination regimen has been studied as an alternative to standard TB therapy to potentially shorten treatment duration or improve efficacy, especially for drug-susceptible pulmonary TB[1][4][6]. While combinations such as moxifloxacin plus rifampin plus pyrazinamide have shown promise in preclinical models[1][4], most clinical regimens substitute either moxifloxacin or isoniazid rather than using all four together routinely.